Case against WARF stem cell patents ends
A nine-year legal challenge to human embryonic stem cell patents ended Tuesday, when the Supreme Court declined to hear the case.
The decision means the Wisconsin Alumni Research Foundation, or WARF, will get to keep its patent rights for the cells, which were discovered in 1998 by University of Wisconsin - Madison scientist James Thompson.
The article by Bradley Fikes also notes:
Loring and two public interest groups, Consumer Watchdog and the Public Patent Foundation, challenged the patents in 2006, and in 2007 succeeded in narrowing WARF's claims to exclude the IPS cells. Loring and the groups continued the challenge on the grounds that as a product of nature, human embryonic stem cells are not patentable.
See earlier posts about this saga on IPBiz.
WARF smokes PubPat, FTCR in last two re-exams of stem cell patents
Nature comments on WARF win over PubPat, FTCR on stem cell patent
ScienceToday on WARF victories over PubPat, FTCR, wherein IPBiz notes of the author: Holden does not mention that the induced pluripotent stem cells themselves are the subject of filed patent applications.
As to iPS, note the previous IPBiz post
The patent world of iPS (stem cells): Yamanaka, Bayer, and iZumi, which includes the text
As a followup, Breitbart reported on 12 Feb 09:
The Japanese unit of German chemical giant Bayer A.G., Bayer Yakuhin Ltd., said Thursday it would sell a set of patents on producing iPS cells, regarded as key in regenerative medicine, to a U.S. venture firm.
The three patents to be sold to iZumi Bio Inc. include Bayer Yakuhin's main method of producing iPS, or induced pluripotent stem cells, which have the potential to grow into any type of human body tissue. Bayer Yakuhin filed for Japanese and international patents on the method in June 2007.
U.S. venture iZumi Bio, based in Mountain View, California, was founded in 2007. It is funded through equity investments by Kleiner Perkins Caufield and Byers and Highland Capital Partners